Ostadian Farshad, Nickkhah Sona, Farrahi Fereydoun, Rad Atefeh Mahdian
Department of Ophthalmology, School of Medicine, Infectious Ophthalmologic Research Center, Ahvaz, Iran.
Resident of Ophthalmology, Department of Ophthalmology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Family Med Prim Care. 2021 Oct;10(10):3820-3824. doi: 10.4103/jfmpc.jfmpc_721_21. Epub 2021 Nov 5.
Corneal collagen cross-linking (CXL) with riboflavin and ultraviolet-A (UVA) is a new technique of mechanical stability of the cornea and prevention of keratoconus progression. The present study aimed at the evaluation of the changes in the corneal volume (CV), volume, and the angle of anterior chamber in keratoconus patients using the Pentacam after CXL.
This prospective study was performed on 48 eyes of 24 patients (including 12 men, 17-33 years old) with progressive keratoconus undergoing CXL treatment at collagen cross-linking Imam Khomeini Hospital in Ahvaz in 2019. The CV (CV) and anterior chamber parameters such as anterior chamber volume (ACV) and anterior chamber angle (ACA) were measured using the Pentacam before CXL and at 6 and 12 months after CXL. Also, all of the patients were evaluated in terms of best-corrected visual acuity (BCVA), during the follow-up.
The pre-CXL values of BCVA was significantly lower than the post-CXL values in 6 and 12 months (0.18 ± 0.11, 0.15 ± 0.10, and 0.11 ± 0.10, respectively, < 0.0001). In general, there was a significant improvement in the BCVA ( < 0.0001), a significant decrease in the CV ( = 0.001), and a significant increase in the ACV ( < 0.0001), and angle ( < 0.0001) 6 and 12 months after CXL.
It seems that CXL has a positive effect on the anterior chamber parameters (ACV and ACA) and CV after 6 months and 1 year in the treatment of keratoconus patients. In addition, the visual acuity improves after CXL. Finally, further studies with a higher sample size and longer follow-up periods are recommended.
核黄素与紫外线A(UVA)交联的角膜交联术(CXL)是一种增强角膜机械稳定性及预防圆锥角膜进展的新技术。本研究旨在通过Pentacam评估圆锥角膜患者在接受CXL治疗后角膜体积(CV)、前房容积和前房角的变化。
本前瞻性研究于2019年在阿瓦士的伊玛目·霍梅尼医院对24例(包括12名男性,年龄17 - 33岁)接受CXL治疗的进展期圆锥角膜患者的48只眼进行。在CXL术前以及术后6个月和12个月,使用Pentacam测量CV以及前房参数,如前房容积(ACV)和前房角(ACA)。此外,在随访期间对所有患者进行最佳矫正视力(BCVA)评估。
术前BCVA值显著低于术后6个月和12个月的值(分别为0.18±0.11、0.15±0.10和0.11±0.10,P<0.0001)。总体而言,CXL术后6个月和12个月时,BCVA有显著改善(P<0.0001),CV显著降低(P = 0.001),ACV和前房角显著增加(P<0.0001)。
CXL似乎在治疗圆锥角膜患者6个月和一年后,对前房参数(ACV和ACA)和CV有积极影响。此外,CXL术后视力有所改善。最后,建议进行样本量更大、随访期更长的进一步研究。